Ferrer Internacional

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents aimed at treating multidrug-resistant (MDR) Gram-negative infections. Established in 2014, the company utilizes its innovative PasNas drug discovery platform to identify pathogen-specific antibacterial properties of various molecules. This platform not only focuses on potent antibacterial activity but also emphasizes the importance of favorable pharmacokinetics and toxicological profiles to enhance the likelihood of success in clinical development. ABAC Therapeutics seeks to provide first-in-class therapeutic alternatives for patients suffering from infections caused by antibiotic-resistant bacterial pathogens, particularly targeting the significant challenge posed by the major MDR Gram-negative bacteria. As of November 2019, the company operates as a subsidiary of Tibidabo Ventures.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, specializing in the research, development, and commercialization of innovative products for the acute treatment of central nervous system conditions. The company utilizes its proprietary Staccato system, which vaporizes drug formulations into an aerosol for inhalation, allowing for rapid delivery and therapeutic onset. Its primary product, ADASUVE, is an inhalation powder used for the acute treatment of agitation associated with schizophrenia and bipolar I disorder in adults. Additionally, Alexza is developing AZ-002 for acute repetitive seizures and AZ-007 for insomnia, both utilizing the Staccato technology. Founded in 2001, the company has also formed a collaboration with Grupo Ferrer Internacional S.A. In 2016, Alexza became a subsidiary of Ferrer Therapeutics, Inc.

Venter Pharma SL is a biotech company based in Alcobendas, Spain, specializing in the development of diagnostic drugs for lactose intolerance and other digestive disorders. Founded in 2003, the company emerged from research conducted by PhD. Juan José Aragón Reyes and Alfonso Fernández Mayoralas at the Autonomous University of Madrid and the Spanish National Research Council. Venter Pharma focuses on creating innovative solutions for high-prevalence digestive pathologies, particularly lactose intolerance and inflammatory illnesses. Its flagship product, LacTEST®, utilizes a novel active substance called Gaxilose to facilitate accurate diagnosis, aiming to simplify and enhance the effectiveness of clinical evaluations. Through its efforts, Venter Pharma seeks to provide patients with advanced treatment options that promote faster recovery.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.